Skip to main content

Table 4 Cost of TKI therapy and cost of related unwanted effects (UE). Amounts are presented in MXN pesos

From: Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

 

Afatinib

(n = 40)

Erlotinib

(n = 26)

Gefitinib

(n = 33)

p-value

Mean (SD)

Median

Mean (SD)

Median

Mean (SD)

Median

TKI cost

Daily cost

722 (130)

765

794 (96)

819

451 (0)

451

<  0.001

Total cost

337,325 (299,832)

238,298

200,506 (137,831)

183,384

149,645 (107,139)

126,299

<  0.001

UE cost

Medications

6846 (21,203)

2485

3479 (5727)

897

2212 (4762)

98

<  0.05

Consultation

4373 (5751)

1732

3797 (4382)

2598

4304 (6125)

1732

0.843

Total

11,219 (23,734)

6948

7276 (8498)

5267

6516 (8986)

2719

0.262

TOTAL

TKI + UE

348,544 (311,386)

246,258

207,782 (143,566)

186,685

156,161 (111,330)

126,299

<  0.001